Renaissance Pharma Ltd.

This study tests whether adding an antibody drug called hu14.18K322A to standard chemotherapy helps children with high-risk neuroblastoma, a rare but aggressive childhood cancer. About 144 children and teens aged 18 months to 18 years will receive the combination over up to 12 cy…